Development and characterization of a unique anti-IgE mouse monoclonal antibody cross-reactive between human and canine IgE

Akiko Kumagai¹ | Takuya Nara¹,² | Mizuho Uematsu¹ | Yoko Kakinuma¹ | Takashi Saito² | Kenichi Masuda¹,²

¹Animal Allergy Clinical Laboratories Inc., Sagamihara, Kanagawa, Japan
²Vaccine Innovation Laboratory, RIKEN Cluster of Science, Technology and Innovation Hub, RIKEN Baton Zone Program, RIKEN, Yokohama Institute, Yokohama, Kanagawa, Japan

Correspondence
Kenichi Masuda, Animal Allergy Clinical Laboratories Inc., SIC-2#301 5-4-20 Nishishamamoto, Midori-ku, Sagamihara, Kanagawa, 252-0131, Japan.
Email: masuda@aacl.co.jp

Abstract

Background: The efficacy assessment of human anti-IgE monoclonal antibodies (mAbs) in animal models before clinical trials is hampered due to the lack of cross-reactivity of anti-IgE mAbs between species.

Objective: We developed CRE-DR (an anti-dog IgE monoclonal antibody), an anti-IgE mouse mAb that recognizes canine and human IgE, and then examined its IgE specificity and cross-reactivity between three animal and human species.

Methods: After mouse immunization with a synthetic peptide derived from canine IgE (282-NTNDWIEGETYYC294), we generated a hybridoma producing CRE-DR. The CRE-DR purified from the ascites of hybridoma-inoculated mice was used for ELISA and Western blot analysis to examine reactivity to dog, human, and rodent IgEs as well as recombinant bovine serum albumin (BSA)-conjugated to canine, human, and rodent IgE amino acid peptides corresponding to the immunizing sequence. We then performed enzyme-linked immunosorbent assays (ELISAs) for dog IgE using sera from dogs with atopic dermatitis (AD) after inhibition with canine IgE and IgG. The amino acid sequence recognized by CRE-DR was identified by ELISA using synthetic peptides.

Results: CRE-DR is a monoclonal mouse IgG1κ specific for dog IgE, and the ELISA values in atopic dog sera were inhibited by dog IgE, but not dog IgG. The binding of CRE-DR to human IgE was relatively maintained, but not to rodent IgEs, which results were confirmed with the BSA-conjugated IgE peptides of the various species. The CRE-DR reactivity was supported by the comparison of amino acid sequence of CRE-DR epitope, DWIEGETYYC, in dog IgE; one, two, and three amino acids were substituted in the human, rat, and mouse IgE epitopes, respectively.
Conclusions and Clinical Relevance: CRE-DR is a mAb cross-reactive to dog and human IgEs, which can allow the use of a dog model of allergy to test the efficacy of a CRE-DR-derived anti-IgE therapeutic mAb before human clinical trials.

KEYWORDS
animals, epitopes, humans, IgE | monoclonal antibody

1 | INTRODUCTION

The discovery of IgE as a key molecule in type I hypersensitivity has had a great impact on our understanding of the pathogenesis of allergic diseases. IgE binds to the high-affinity IgE receptor (FcεRI) expressed mainly on mast cells and basophils. When IgE molecules are cross-bridged, mast cells degranulate and release multiple inflammatory mediators, such as histamine, and induce the acute inflammation typical of type I hypersensitivity. The targeting of IgE by anti-IgE monoclonal antibodies (mAbs) has been successful to control clinical signs in IgE-mediated allergic diseases. Omalizumab was the first approved anti-IgE therapeutic mAb shown to reduce serum IgE levels in human patients with asthma and chronic spontaneous urticaria. Ligelizumab, another anti-IgE mAb, has a higher effect on serum IgE reduction due to a higher affinity for IgE than omalizumab. However, as both antibodies seem unable to eliminate IgE-producing B cells, their effects to control clinical symptoms of IgE-mediated disease appear limited. In contrast, quilizumab was a different anti-IgE mAb that targeted IgE-producing B cells by linking to the M1 prime protein, an IgE membrane-binding protein on B cells, but it did not bind to serum IgE. Unfortunately, serum IgE was decreased in Phase II clinical trial of human patients receiving quilizumab, thus indicating that the quilizumab also bound to serum IgE before it reached IgE-producing B cells, and this led to the cancellation of its development.

Animal models of allergy could be used to reduce the risk of failure before testing anti-IgE therapeutic mAbs in human clinical trials. Mice transgenic for the human FcεRIα gene have been used to evaluate the inhibition of anti-IgE humanized antibodies on recombinant human IgE bound to the neo-expressed human FcεRIα in vivo. Unfortunately, such an artificial model that only expresses a single human molecule would be insufficient to investigate complex immune reactions in vivo, such as antibody-dependent cellular cytotoxicity, antibody-dependent cellular phagocytosis, or the effect of anti-IgE therapeutic mAbs. In contrast, the dog has been long known to suffer from spontaneous IgE-mediated reactions that result in clinical disease manifestations, such as atopic dermatitis (AD). Serum antigen-specific IgE increased after allergen exposure and AD flares in dogs. The IgE-mediated origin of such reactions was proven by basophil-histamine release. A comparison of immunologic characteristics of canine and mouse models of AD confirms the high translational value of canine AD for the human disease homologue. Thus, dogs with AD would be a valid spontaneous model of type I hypersensitivity to evaluate the complex immune effects of human anti-IgE mAbs. However, for this purpose, human anti-IgE mAbs would need to be cross-reactive with canine IgE.

Since the amino acid sequence between IgEs of humans and animals is not highly homologous, it has been difficult to generate an anti-IgE antibody cross-reactive between canine and human IgE. Nevertheless, the IgE amino acid sequence that binds to the FcεRIα appears relatively well-conserved among humans and animals, and a mAb targeting this sequence would be expected to recognize both canine and human IgE. The fine epitope of omalizumab, of human IgE—the IgE binding region to FcεRIα—is also identical in dog IgE, but the reactivity of omalizumab to canine IgE has never been reported. Omalizumab also binds to conformational epitope, and due to the existing conformational changes of IgE, structural differences in IgE would likely have an influence on the binding of omalizumab to dog IgE. For these reasons, a therapeutic mAb cross-reactive between canine and human IgE has not been characterized and developed to date.

In this study, we generated a unique anti-IgE mAb, CRE-DR (an anti-dog IgE monoclonal antibody), cross-reactive between dogs and humans, against a peptide well-conserved between species. The reactivity of CRE-DR was investigated against canine, human, and rodent IgE. Finally, the CRE-DR epitope was mapped to confirm its cross-reactivity.
2 | METHODS

2.1 | Development of the CRE-DR, anti-canine IgE mAb

The peptide for mouse immunization consisted of a 13-mer peptide whose NTNDWIEGETYYC sequence corresponds to the position 282–294 segment of the dog IgE heavy chain (GenBank No. AAA56797.1), because the site was protruded outside in the IgE structure (Protein Data Bank[PDB], identification code 1F6A\(^{17}\) and suspected to have a possible antigenicity in a previous report to develop antiserum against a neighboring site.\(^{18}\) This synthetic peptide, conjugated with keyhole limpet hemocyanin (Sigma-Aldrich Japan Inc.), was injected at the tail base of BALB/c mice. After fusing external iliac lymph node cells and SP2 mouse myeloma cells, a hybridoma producing a monoclonal mouse IgG reactive to both dog IgE mice. After fusing external iliac lymph node cells and SP2 mouse myeloma cells, a hybridoma producing a monoclonal mouse IgG reactive to both dog IgE (Bethyl Laboratories, Inc.) and rat IgE (Invitrogen) was selected by enzyme-linked immunosorbent assay (ELISA) on the cell culture supernatant using donkey-anti-mouse IgG and goat-anti-mouse IgG light chain polyclonal antibodies (Jackson ImmunoResearch Laboratories, Inc.). The obtained mAb, named CRE-DR, was purified with protein G sepharose (Cytiva) from the ascites of mice intraperitoneally inoculated with this hybridoma. The final concentration of purified CRE-DR was measured by absorbance at 280 nm. The CRE-DR mouse IgG subclass was determined using the MAb Isotyping Test Kit (Bio-Rad Laboratories, Inc.). The experiments for hybridoma development and mouse ascites collection had been approved beforehand by the Animal Care and Use Committee of the Cell Engineering Corporation (approval number; S-233) and T.K. Craft Ltd. (approval number; AE190213), respectively.

2.2 | Reactivity of CRE-DR to dog, human, rat, and mouse IgE in ELISA

Commercially available dog IgE (Bethyl Laboratories Inc.), human IgE (Merck KGaA), rat IgE (Thermo Fisher Scientific, Inc.), mouse IgE (BD Pharmingen), and dog IgG (Cappel) were used for fluorescence ELISAs with biotinylated CRE-DR (EZ-Link NHS-PEG12-Biotin) (Thermo Fisher Scientific), using the Gemini XPS microplate reader (Molecular Devices, LLC.) and SoftMax Pro software (Molecular Devices), as reported previously.\(^{19}\)

2.3 | Reactivity of CRE-DR in Western blot analysis

SDS-PAGE was performed with a polyacrylamide linear gradient gel (5%–20%) for IgE reagents of dog (Bethyl Laboratories), human (Merk KGaA), mouse (BD Pharmingen), dog IgG (Cappel), and canine serum albumin (MP Biomedicals) at 2 μg/lane for Coomassie Brilliant Blue staining and 0.1 μg/lane for Western blot analysis under both reduced and nonreduced conditions. For Western blot analysis, the gel was transferred to a PVDF membrane (Bio-Rad Laboratories) and reacted with biotinylated CRE-DR at 1 μg/ml in 10-fold diluted blocking buffer (KAC Co., Ltd) after blocking. The membrane was washed with TBS-0.05% Tween 20 (TBS-T), and bands were visualized with streptavidin-conjugated alkaline phosphatase (F. Hoffmann-La Roche, Ltd.) and 1-Step™ NBT/BCIP Substrate Solution (Thermo Fisher Scientific).

2.4 | Reactivity of CRE-DR to partial peptides of dog, human, and mouse IgE

We produced a recombinant protein with a molecular weight (MW) of 71 kDa by expression in Escherichia coli BL21star (DE3) transfected with a pET-15b vector carrying an N-terminal His-tag sequence followed by a thrombin site and the cloning sites of NdeI and XhoI, between which a synthesized DNA was inserted. From the translated amino- (N-terminus) to the carboxy-terminus (C-terminus), this synthesized DNA encoded a segment of bovine serum albumin (BSA) (GenBank No. BC142272.1; positions 108 to 1856), a GS-linker (GGSGGTGGSGS), and the dog IgE peptide used in the mouse immunization. After the His-tagged recombinant protein was purified by nickel resin, the final concentration in PBS was determined by the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific). Similarly, we synthesized DNAs for the \(^{433}\)GTRDWIEGETYYC\(^{445}\) (GenBank No. AAB59424) and \(^{411}\)VAKDWIEETYQC\(^{423}\) (GenBank No. BAQ 55489.1) peptides, which correspond to the \(^{282}\)NTNDWIEGETYYC\(^{294}\) immunizing dog IgE sequence in the human and mouse IgE, respectively, used as recombinant human and mouse proteins (i.e., BSA-human and BSA-mouse peptides). All of these procedures were outsourced to the GenScript Biotech Corporation. The cross-reactivity of CRE-DR to the peptides and to recombinant BSA (Pierce Chemical) was examined by ELISA.
2.5 | Der f 2 inhibition ELISA

Recombinant silkworm-expressed Der f 2 was prepared as previously reported (a kind gift of Zenoaq Nippon Zenyaku Kogyo, Co., Ltd.).\(^{20}\) We selected serum samples from four allergy-suspected dogs (Dogs 1–4), which we had previously found to have high levels of Der f 2-IgE (data available at 10.6084/m9.figshare.14229335) by ELISA with a slight modification of the previous method using a polyclonal goat anti-dog IgE antiserum (Bethyl Laboratories).\(^{21}\) Der f 2-coated plates and the pre-incubated canine sera at 56°C for 15 min were used to determine serum levels of Der f 2-IgE by the ELISA using CRE-DR, as described above. The reactivity of CRE-DR to Der f 2-IgE was also confirmed by Western blot analysis (data not shown). Using a standard curve generated from the reactivity of the CRE-DR to the BSA-dog-peptide captured by plate-coated anti-His-tag mAb (clone, HIS.H8) (Thermo Fisher Scientific), the concentrations of Der f 2-specific IgE in the dog sera were calculated from the number of molecules of dog IgE (196 kDa MW)\(^{22}\) equimolecular to those of the BSA-dog peptide (71 kDa MW).

Inhibition ELISAs were performed with dog IgE (Bethyl Laboratories) and dog IgG (Cappel) as inhibitors.\(^{19}\) The biotinylated CRE-DR was incubated with dog IgE or dog IgG at different molar ratio, and the canine sera were tested using the Der f 2-IgE ELISA described above. After setting the uninhibited Der f 2-IgE levels at 100%, the inhibition percentages of Der f 2-IgE concentrations were then calculated.

2.6 | Mapping of the CRE-DR epitopes

The original peptide used for mouse immunization, and seven N- or C-truncated fragments of this peptide, were synthesized by a manufacturer (Cosmo Bio Co., Ltd.). Each peptide was conjugated to a 6x His-tagged GGSGGS-peptide at its N-terminus and a GGSGGS linker. To design a capture ELISA, the anti-His-tag mAb (clone, HIS.H8) was immobilized onto the plates to capture the peptides that were then detected by the biotinylated CRE-DR, as described above.

3 | RESULTS

3.1 | CRE-DR specificity to canine IgE

Only one hybridoma cell line produced a mAb reactive to both dog and rat IgE. The mouse IgG subclass of CRE-DR was IgG1κ. CRE-DR specifically recognized dog IgE, but not dog IgG (Figure 1A,C), confirming its specificity to dog IgE.

The CRE-DR binding to the BSA-dog peptide increased in a dose-dependent manner, while that to BSA alone remained low (Figure 1B). The maximum

**FIGURE 1** The reactivity of CRE-DR to dog IgE were examined with enzyme-linked immunosorbent assays (ELISAs) and Western blot analysis. (A) ELISAs with dog IgE (●) or dog IgG-coated (○) plates showed that the CRE-DR was reactive to dog IgE, but not to dog IgG. (B) CRE-DR recognized recombinant bovine serum albumin (BSA) conjugated with the dog IgE immunizing peptide (BSA-dog peptide) (■), but not recombinant BSA alone (□). These assays were independently repeated three times; the values represent the means, and the error bars are the standard deviation. (C) Western blot analysis for dog IgE (lane 1), dog IgG (lane 2), and canine serum albumin (lane 3) showed the specific reaction of CRE-DR to dog IgE, especially heavy chain, not dog IgG. CBB, Coomasie Brilliant Blue.
reactivity with the lowest background was obtained at 500 pM, which was determined to correspond to 35.5 ng/ml, after conversion using the MW of BSA-dog peptide. These results support that CRE-DR is a canine-IgE-specific mAb.

In the data of Western blots analysis (Figure 1C), CRE-DR was only reactive to the heavy chain of dog IgE, which contained the target peptide of CRE-DR, indicating specific reaction of CRE-DR.

3.2 | Allergen-specific IgE detection in canine sera using CRE-DR

Der f 2-specific IgE in the four canine sera was quantitatively measured after conversion of the fluorescence units (FU)s to IgE concentrations in nanograms per milliliter, using a standard curve, as in Figure 1B. The four dogs were all found to have elevated Der f 2-specific IgE levels (range: 991–1722 ng/ml). The preincubation of CRE-DR with dog IgE inhibited the detection of Der f 2-IgE in a dose-dependent manner of IgE to between 35% and 42% of those without inhibitor. That with dog IgG did not (Figure 2), confirming the specificity of CRE-DR for native dog IgE, even in sera that contain an amount of IgG larger than that of IgE.

3.3 | Cross-reactivities of CRE-DR to human and rodent IgE

ELISA reactivity of CRE-DR to human IgE was reduced only to lesser extent than that to canine IgE, but the reactivity to rat IgE was largely lost, and that to mouse IgE was completely disappeared (Figure 3). The tendency was confirmed by the results of Western blot analysis that showed an apparent band for dog IgE and a faint band for human IgE, but not for mouse IgE in the non-reduced condition, although in the reduced condition, the heavy chain of dog IgE and human IgE showed an apparent band with an equal density (Figure 4), indicating the specificity of CRE-DR binding for the target region existing in IgE heavy chain.

The cross-reactivity of CRE-DR to human IgE was also confirmed with Western blot analysis using BSA-peptides (Figure 5A), showing the reactivity of CRE-DR to BSA-dog peptide and BSA-human peptide, not to BSA-mouse peptide. The reactivities of CRE-DR to the BSA-dog and BSA-human peptides in ELISA were nearly identical at the molarity of 5600 pM, while that to the BSA-mouse peptide was approximately 10-times lower (Figure 5B). At the concentration of 560 pM, the reactivities to BSA-human and BSA-mouse peptide were reduced (Figure 5B)—a trend similar to the difference in reactivities of the CRE-DR to the dog, human, and mouse IgE at 1000 ng/ml (Figure 4). The tendency of CRE-DR to cross-react with BSA-human peptide and not with BSA-mouse peptide was also confirmed by Western blot analysis (Figure 5A).
3.4 Epitope mapping of CRE-DR and reactivities to IgEs

The CRE-DR reactivity disappeared when four amino acids from the N-terminus (Peptide No.3) and at least one amino acid from the C-terminus (Peptide No. 4–8) were deleted from the original peptide (Peptide No. 1) (Figure 6). The reactivity to the Peptide No.2 (DWIEGETYYC) was almost identical to that of the original, confirming that it contains the main epitope of CRE-DR.

One amino acid difference was found between the canine and human CRE-DR epitopes: at position 293 in the dog IgE sequence, the tyrosine (Y) is replaced by a glutamine (Q) in the human one (GenBank No. AAB59424) (Table 1). There are two and three additional amino acid changes when comparing the canine to the rat and mouse epitope sequences, respectively.

4 DISCUSSION

The anti-IgE mouse IgG1x mAb CRE-DR was specific for dog IgE—but not dog IgG—and cross-reactive with human, but not rodent IgE, which were confirmed by ELISAs and Western blot analysis. The DWIEGETYYC amino acid sequence of the CRE-DR epitope on dog IgE is well-conserved with that of human IgE, as there is only one amino acid difference (Table 1). Indeed, human IgE and the BSA-human peptide were still recognized by CRE-DR, while the reactivity to mouse IgE and the BSA-mouse peptide, with its three amino acid substitution in the CRE-DR epitope, was almost completely lost.

The CRE-DR specificity for dog IgE was also confirmed with the inhibition ELISAs using dog serum from clinical cases of allergy, indicating that CRE-DR could react not only with IgE reagents but also native dog IgE.

Since CRE-DR was found to be reactive to dog and human IgEs, CRE-DR cross-reactivity to IgEs of the other animals could be speculated when compared the amino acid sequence of CRE-DR epitope among those of animals’ IgEs. Pig IgE precursor (GenBank: AAC48776.1) showed the same amino acid sequence of CRE-DR epitope as dog IgE, presumably recognized by CRE-DR. Cow IgE constant region (GenBank: ANN46381.1) showed one amino acid substitution (Iso to Val at the position of 287) in the dog peptide. Cat IgE (GenBank: AAD20023.1) showed two amino acid substitutions (Iso to Val at 287 and Tyr to Gln at 292) in the dog peptide. The substitution of one amino acid will not be considered as a big obstacle for CRE-DE cross-reactivity, since Iso and Val are similar in physiological properties of the amino acids. An amino acid substitution in the dog peptide from Tyr to Lys at 293 was observed in horse IgE (GenBank: CAC44498.1), which physiological properties are not similar, affecting the binding of CRE-DR. It is suspected that CRE-DR may lose the reactivity to the horse IgE in some degree.

The conformational structure of human IgE (PDB, 1F6A) showed that the segment corresponding to the CRE-DR epitope protrudes outward with the alpha helix (consisting of amino acids of DWIE, a N-terminal part of CRE-DR epitope) followed by the beta sheet (consisting of amino acics of TYQC, a C-terminal part of CRE-DR epitope) with a turn structure of glycine and glutamic acid.
There is an N-linked glycosylation site on an asparagine, 15 amino acid N-terminally from the epitope. This N-glycosylation, rich in mannoses, is indispensable for the “open” (oval shape of IgE constant region) structure of the CH3 domain that allows the binding of IgE to FcεRI. Therefore, the epitope site of CRE-DR could be extending outwardly, which might explain its immunogenicity. In fact, polyclonal antibodies have been generated against a peptide next to an epitope of CRE-DR. The success of CRE-DR development might be, at least in part, due to the selection of a region accessible to IgG antibodies.

There is some value in evaluating if the CRE-DR, as a mAb whose epitope is clearly identified, would recognize the IgE of other mammalian species. Previously, we created the CRE-DM, a rat mAb cross-reactive between dog and mouse IgE, but its epitope was not determined. Since the anti-human IgE omalizumab mAb recognizes three consecutive amino acids that are conserved between human and canine IgE, one would expect it to be cross-reactive between human and dog IgE. In preliminary experiments, however, we found that the omalizumab did not bind to dog IgE, suggesting that any cross-reactivity of anti-IgE mAbs between humans and dogs requires the recognition of not only similar linear amino acid sequences, but also a similar conformation between those IgEs. In fact, it was reported that omalizumab recognized amino acids of human IgE in a non-sequential manner, which would affect its recognition of canine IgE. Since the need of conformational epitopes is a major obstacle to antibody development—at least with the existing technology—a mAb such as CRE-DR cannot be easily generated.

Due to the unique ability of CRE-DR to recognize both human and canine IgE, a dog model of IgE-mediated
Allergy could be utilized to investigate the efficacy of anti-IgE therapeutic mAbs derived from the CRE-DR. A caninized CRE-DR mAb could be first tested in dogs with spontaneous IgE-mediated (i.e., “extrinsic”), increased serum IgE) AD to detect if this mAb could prevent or reduce clinical signs. Then, the results in dogs would be informative as preclinical data for the development of a humanized antibody derived from the CRE-DR. Due to the closeness of IgE-mediated allergic reaction between canine and human AD,13 a therapeutic success in dogs would reduce the inherent risk that exists when translating mouse studies to clinical trials in humans. This advantage has never been proposed by the other anti-IgE antibody drugs such as omalizumab and ligelizumab, which cross-reactivity to animal’s IgEs was not shown.

In summary, we generated CRE-DR, a unique mAb specific for dog IgE that also recognizes human IgE; such cross-reactivity was confirmed by the recognition of both IgE and its derived recombinant peptides in dogs, humans, and mice, and the identification of the CRE-DR epitope. An anti-human IgE therapeutic mAb derived from the CRE-DR could be developed after validation of the efficacy of a caninized CRE-DR mAb on a canine model of IgE-mediated AD. The caninized CRE-DR itself will also be the first antibody drug for IgE in dogs. Thus, the cross-reactivity of CRE-DR should be highly considered to be useful for the treatment of allergy in both human and animals.

ACKNOWLEDGMENT

We would like to thank for Dr. Mark J. Micallef and Mr. Toshihiro Tsukui from Zenoaq Nippon Zenyaku Kogyo Co., Ltd. (Fukushima, Japan) for kindly providing the recombinant Der f 2 protein and Dr. Thierry Olivry from North Carolina State University for reviewing the manuscript. The studies in this report were self-funded.

CONFLICT OF INTERESTS

K. Masuda is a stockholder and Chief Executive Officer of the Animal Allergy Clinical Laboratories, Inc.; K. Masuda and T. Saito are inventors in the patent application related to the CRE-DR.

ETHICS STATEMENT

There is no human clinical study. All mouse-based experiments had been approved beforehand by the Animal Care and Use Committee of the companies performing the contract research.

AUTHOR CONTRIBUTIONS

Performed experiments and analyzed data: Akiko Kumagai. Performed experiments: Takuya Nara, Mizuho Uematsu, and Yoko Kakinuma. Analyzed and interpreted the data, contributed the final writing: Takashi Saito. Conceived the original idea, planned and directed all the experiments, supervised the project, analyzed and interpreted data, wrote the manuscript: Kenichi Masuda.

DATA AVAILABILITY STATEMENT

The raw data are available at the repository (10.6084/m9.figshare.14229335).

ORCID

Kenichi Masuda http://orcid.org/0000-0002-0784-3284

REFERENCES

1. Ishizaka K, Ishizaka T. Physicochemical properties of reaginic antibody. 3. Further studies on the reaginic antibody in gamma-A-globulin preparations. J Allergy. 1966;38(2):108-119.
2. Metzger H, Alcaraz G, Hohman R, Kinet JP, Pribluda V, Quarto R. The receptor with high affinity for immunoglobulin E. Annu Rev Immunol. 1986;4:419-470.
3. Ogawa Y, Grant JA. Mediators of anaphylaxis. Immunol Allergy Clin North Am. 2007;27(2):249-260vii.
4. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108(2):184-190.
5. Gasser P, Tarchevskaya SS, Guntern P, et al. The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab. Nat Commun. 2020;11(1):165.
6. Zheng L, Li B, Qian W, et al. Fine epitope mapping of humanized anti-IgE monoclonal antibody omalizumab. Biochem Biophys Res Commun. 2008;375(4):619-622.
7. Korn S, Hasler I, Friedner F, et al. Monitoring free serum IgE in severe asthma patients treated with omalizumab. Respir Med. 2012;106(11):1494-1500.
8. Maurer M, Rosén K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368(10):924-935.
9. Jones J, Shepherd J, Hartwell D, et al. Omalizumab for the treatment of severe persistent allergic asthma. Health Technol Assess. 2009;13(Suppl 2):31-39.
10. Harris JM, Maciuca R, Bradley MS, et al. A randomized trial of the efficacy and safety of quinبلumab in adults with inadequately controlled allergic asthma. Respir Res. 2016;17:29.
11. Masuda K, Sakaguchi M, Saito S, et al. In vivo and in vitro tests showing sensitization to Japanese cedar (Cryptomeria japonica) pollen allergen in atopic dogs. J Vet Med Sci. 2000;62(9):995-1000.
12. Masuda K, Sakaguchi M, Saito S, et al. Seasonal atopic dermatitis in dogs sensitive to a major allergen of Japanese cedar (Cryptomeria japonica) pollen. Vet Dermatol. 2002;13(1):53-59.
13. Martel BC, Lovato P, Baumer W, Olivry T. Translational animal models of atopic dermatitis for preclinical studies. Yale J Biol Med. 2017;90(3):389-402.
14. Breaux B, Deiss TC, Chen PL, et al. The Florida manatee (Trichechus manatus latirostris) immunoglobulin heavy chain suggests the importance of clan III variable segments in repertoire diversity. Dev Comp Immunol. 2017;72:57-68.
15. Griot-Wenk ME, Obexer-Ruff G, Fluri A, Marti E. Partial sequences of feline and caprine immunoglobulin epsilon heavy chain cDNA and comparative binding studies of recombinant IgE fragment-specific antibodies across different species. *Vet Immunol Immunopathol.* 2000;75(1-2): 59-69.

16. Wan T, Beavil RL, Fabiane SM, et al. The crystal structure of IgE Fc reveals an asymmetrically bent conformation. *Nat Immunol.* 2002;3(7):681-686.

17. Garman SC, Wurzburg BA, Tarchevskaya SS, Kinet JP, Jardetzky TS. Structure of the Fc fragment of human IgE bound to its high-affinity receptor Fc epsilonRI alpha. *Nature.* 2000;406(6793):259-266.

18. Peng Z, Liu Q, Wang Q, Rector E, Ma Y, Warrington R. Novel IgE peptide-based vaccine prevents the increase of IgE and down-regulates elevated IgE in rodents. *Clin Exp Allergy.* 2007; 37(7):1040-1048.

19. Okayama T, Matsuno Y, Yasuda N, et al. Establishment of a quantitative ELISA for the measurement of allergen-specific IgE in dogs using anti-IgE antibody cross-reactive to mouse and dog IgE. *Vet Immunol Immunopathol.* 2011;139(2-4): 99-106.

20. Chan WY, Selvarajah GT, Ajat M, Suzuki R, Tsukui T. The detection of house dust mite *Dermatophagoides farinae*, Der f 2 and Zen-1 allergen-specific immunoglobulin E antibodies in dogs with atopic dermatitis in Malaysia. *Vet Immunol Immunopathol.* 2019;212:43-49.

21. Masuda K, Tsujimoto H, Fujiwara S, et al. IgE sensitivity and cross-reactivity to crude and purified mite allergens (Der f 1, Der f 2, Der p 1, Der p 2) in atopic dogs sensitive to *Dermatophagoides* mite allergens. *Vet Immunol Immunopathol.* 1999; 72(3-4):303-313.

22. Peng Z, Arthur G, Kierek-Jaszczuk D, et al. Purification and identification of polyclonal IgE antibodies from ragweed-sensitized dog sera. *Int Arch Allergy Immunol.* 1993;102(2): 176-184.

23. Shade KT, Platzer B, Washburn N, et al. A single glycan on IgE is indispensable for initiation of anaphylaxis. *J Exp Med.* 2015;212(4):457-467.

**How to cite this article:** Kumagai A, Nara T, Uematsu M, Kakinuma Y, Saito T, Masuda K. Development and characterization of a unique anti-IgE mouse monoclonal antibody cross-reactive between human and canine IgE. *Immun Inflamm Dis.* 2021;9:1740-1748. https://doi.org/10.1002/iid3.531